What Diseases Do Mosquitoes Carry and Spread?

Mosquitoes transmit a surprisingly long list of diseases, from parasitic infections like malaria and lymphatic filariasis to viral illnesses including dengue, Zika, West Nile, and chikungunya. Collectively, mosquito-borne diseases kill hundreds of thousands of people each year and sicken hundreds of millions more. Not every mosquito species carries every pathogen, though, and the biology behind how these insects pick up and deliver diseases is more variable than most people realize.

Malaria

Malaria remains the deadliest mosquito-borne disease globally. It is caused by Plasmodium parasites, and the life cycle depends on female Anopheles mosquitoes as the obligate vector. The parasite alternates between a vertebrate host and the mosquito, undergoing sexual reproduction inside the insect before producing sporozoites that migrate to the mosquito’s salivary glands and get injected into the next person it bites.¹ Five Plasmodium species infect humans, with P. falciparum causing the most severe illness and most deaths, primarily in sub-Saharan Africa. P. vivax is the most geographically widespread and can lie dormant in the liver for months before causing relapses.

What makes malaria transmission particularly unpredictable is how sporozoites move through the mosquito. They must travel from the salivary cavity into the salivary duct, where only a limited number are present at any time, organized in single-file bundles. A considerable fraction of mosquitoes with infected salivary glands actually deliver no sporozoites during a given bite, meaning not every bite from an infected mosquito results in infection.² The parasite’s ability to produce and deliver those sporozoites also depends on how well-nourished the mosquito is. Parasites in well-fed mosquitoes produce about 1.7 times more sporozoites than those in sugar-only-fed mosquitoes, and the parasites appear to adjust their growth rate depending on available resources.³

Dengue

Dengue is the most common mosquito-borne viral disease worldwide, with an estimated 100 to 400 million infections per year. It is caused by four closely related viruses (dengue 1 through 4), all transmitted by Aedes aegypti and, to a lesser extent, Aedes albopictus mosquitoes. Most infections produce mild flu-like symptoms or no symptoms at all. The trouble comes with repeat infections. Because the four dengue viruses are distinct enough that immunity to one does not protect against the others, a second infection with a different type can be far more dangerous.

This happens through a process where antibodies from a first infection, rather than neutralizing a new dengue type, actually help the virus enter more cells and replicate faster. Research on a long-term pediatric cohort showed that the risk of severe dengue was highest within a narrow range of pre-existing antibody levels, while high antibody titers were protective against symptomatic disease altogether.⁴ This complicates vaccine development considerably, because a vaccine that raises antibodies to intermediate levels could, in theory, increase severe disease risk rather than prevent it. It is one reason the first licensed dengue vaccine ended up being recommended only for people who had already had at least one prior dengue infection.

Zika

Zika grabbed global attention during the 2015–2016 outbreak in the Americas, but the virus had been circulating in Africa and Southeast Asia for decades before that. Spread mainly by Aedes aegypti, Zika causes mild illness in most adults: a low fever, rash, joint pain, and red eyes that clear up within a week or two. The real danger is to pregnant women and their developing babies. Zika can cross the placenta and infect fetal brain tissue, causing severe congenital malformations, most notably microcephaly.⁵

Long-term follow-up of children exposed to Zika in utero has revealed that the neurological effects extend well beyond head size. Reviews of developmental outcomes in these children document a range of issues including vision and hearing problems, motor delays, and cognitive difficulties, underscoring that Zika’s impact on the developing brain can be broad and lasting.⁶ Unlike dengue, Zika can also be sexually transmitted, which added an unusual wrinkle for mosquito-borne disease control efforts.

Chikungunya

Chikungunya is another Aedes-transmitted virus, and while it rarely kills, it can leave lasting misery. The name comes from a word in the Kimakonde language meaning “to become contorted,” a reference to the stooped posture of sufferers. The acute phase typically arrives two to seven days after a bite and features sudden high fever alongside severe, symmetrical joint pain hitting the wrists, ankles, and fingers. A maculopapular rash, headache, and fatigue are also common.⁷

The acute symptoms usually resolve within one to two weeks, but what sets chikungunya apart from many other mosquito-borne infections is its chronic phase. Joint pain, fatigue, and musculoskeletal problems can persist for months or even years, resembling rheumatoid arthritis badly enough to limit daily activities and significantly reduce quality of life.⁸ Severe complications like encephalitis or Guillain-Barré syndrome are uncommon but can occur, particularly in newborns, older adults, and people with pre-existing health conditions.

West Nile Virus

West Nile virus (WNV) is maintained globally in a cycle between Culex mosquitoes and birds, with humans as incidental dead-end hosts who get infected when the virus spills over from that bird-mosquito cycle.⁹ About 80 percent of human infections cause no symptoms at all. Most of the remaining 20 percent cause a fever that resolves on its own. But roughly 1 in 150 infections leads to neuroinvasive disease, which can include encephalitis or meningitis, and which can be fatal or leave permanent neurological damage.

The ecology behind WNV transmission is surprisingly species-specific. Research comparing bird species found that American robins infected far more mosquitoes than common grackles at the same level of virus in the blood, and even when grackles had four to ten times more circulating virus, robins still infected a significantly greater proportion of mosquitoes.¹⁰ This means the bird community in a given area matters enormously for predicting human WNV risk, and it is one reason the virus can seem unpredictable from year to year in temperate regions.

Lymphatic Filariasis

Not all mosquito-borne diseases are caused by viruses or single-celled parasites. Lymphatic filariasis is caused by parasitic roundworms, mainly Wuchereria bancrofti and two Brugia species, that are transmitted by multiple mosquito genera. In rural Africa and Asia, Anopheles species (the same genus that carries malaria) are the primary vectors. In Pacific island nations, various Aedes species take over that role.¹¹ In parts of Malaysia, the picture is even more complex, with multiple mosquito species transmitting different Brugia and Wuchereria species alongside zoonotic filarial worms.¹²

The worms lodge in the lymphatic system, where they can live for years. Chronic infection may eventually block lymph drainage, causing the dramatic tissue swelling known as elephantiasis. Because the disease develops slowly and the early stages are often symptom-free, people in endemic areas can carry the worms for years without knowing. Mass drug administration programs have reduced filariasis in many regions, but it remains endemic in parts of Africa, South and Southeast Asia, and the Pacific.

Heartworm in Dogs and Pets

Mosquitoes also transmit diseases that matter enormously to pet owners. Dog heartworm, caused by the filarial nematode Dirofilaria immitis, is an obligate mosquito-borne pathogen carried by at least 26 mosquito species in the United States alone.¹³ The worms mature inside the dog’s heart and pulmonary arteries, eventually causing heart failure if untreated. Research in California found significant associations between local mosquito abundance and heartworm cases, with specific Aedes and Culex species driving transmission in different regions of the state.¹⁴ Year-round preventive medication is the standard recommendation in most of the U.S., but compliance is uneven, and heartworm remains common.

Emerging Threats

The list of mosquito-borne diseases is not static. Mayaro virus, an alphavirus related to chikungunya, circulates in South America and produces symptoms that are often indistinguishable from dengue or chikungunya: fever, joint pain, and rash. Severe cases can involve chronic joint inflammation, neurological complications, or hemorrhage.¹⁵ Co-circulation of multiple similar arboviruses in the same regions makes clinical diagnosis extremely difficult and complicates surveillance. If Mayaro establishes efficient transmission in Aedes aegypti, it could spread to the same urban areas already dealing with dengue and Zika.

Other viruses on epidemiologists’ watch lists include Rift Valley fever, Japanese encephalitis, Eastern equine encephalitis, and yellow fever, all of which are transmitted by mosquitoes and all of which have shown the capacity for sudden outbreaks when ecological conditions shift. The fundamental worry is that a pathogen currently limited to a sylvatic cycle in forests could adapt to urban Aedes mosquitoes and explode into human populations, much as Zika did.

Why Some People Get Bitten More

Almost everyone knows someone who claims mosquitoes target them specifically. Research confirms this is real and not imagined. A study using gas chromatography to analyze human skin odor found that people who are highly attractive to mosquitoes have significantly higher levels of certain carboxylic acids on their skin. When researchers diluted the skin scent of the most attractive person, mosquitoes could no longer distinguish that person from the least attractive subjects.¹⁶

Separate work identified specific compounds associated with high and low attractiveness. People who attracted more mosquitoes had higher levels of compounds like decanoic acid on their skin, while less attractive individuals had elevated levels of certain cyclopentanedione derivatives that showed significant repellent effects in behavioral tests.¹⁷ Most of these compounds tie back to fatty acid metabolism, meaning your skin chemistry and microbiome likely play a bigger role than blood type, diet, or clothing color, despite the folk wisdom around those factors. There is also evidence that malaria parasites can manipulate mosquito behavior, making infected mosquitoes more attracted to human hosts once the parasite has matured enough to be transmissible.¹⁸

How Climate Change and Urbanization Are Expanding the Map

The geographic range of mosquito-borne disease is shifting. Modeling of 18 mosquito species under various climate scenarios projected dramatic habitat changes by mid-century and beyond. Under the most aggressive warming scenario, Aedes albopictus (the Asian tiger mosquito, a competent dengue and chikungunya vector) was projected to expand its suitable habitat by over 180 percent, and Culex tritaeniorhynchus (a Japanese encephalitis vector) by over 230 percent, while some northern-adapted Anopheles species saw their habitat shrink.¹⁹ Even moderate warming scenarios showed meaningful range expansion for the species most closely tied to human disease.

Urbanization compounds the problem. Cities create warmer microclimates and an abundance of artificial water-holding containers, from discarded tires to rooftop gutters, that Aedes mosquitoes thrive in. Research in Hanoi found that Aedes species were especially abundant in domestic habitats created by man-made materials, while Culex species dominated in larger water bodies including both man-made and natural ones.²⁰ Urban heat islands, higher pollution levels, and dense human populations all favor the development of mosquito species that are already the most efficient disease vectors.²¹

New Approaches to Mosquito Control

Traditional mosquito control relies heavily on insecticides, especially pyrethroids used in bed nets and indoor spraying. But resistance is becoming a serious problem. Mosquito populations exposed to pyrethroid-treated nets for extended periods have evolved elevated levels of enzymes that break down diverse chemical compounds, and testing has found that some newer insecticide classes are also vulnerable to this cross-resistance.²² Adding synergist compounds like piperonyl butoxide (PBO) to nets can restore effectiveness, but the arms race between chemistry and mosquito evolution is relentless.

One of the most promising newer strategies involves Wolbachia, a naturally occurring bacterium that can be introduced into Aedes aegypti mosquitoes. Mosquitoes carrying the wMel strain of Wolbachia showed roughly 1,500-fold less dengue virus replication compared with uninfected mosquitoes.²³ The same Wolbachia strain also reduces the mosquitoes’ ability to transmit Zika virus, making it a multi-disease tool.²⁴ Large-scale releases of Wolbachia-carrying mosquitoes are already underway in cities across several countries, and early results from field deployments have been encouraging.

Gene drive technology represents an even more radical approach. A CRISPR-based gene drive targeting a gene called doublesex in Anopheles gambiae, the primary African malaria mosquito, spread to 100 percent of caged mosquitoes within 7 to 11 generations while progressively reducing egg production until the population collapsed entirely.²⁵ Earlier gene drive constructs targeting female fertility genes showed transmission rates to offspring above 91 percent in the same species.²⁶ For West Nile virus control, researchers have developed a self-limiting version of the technology in Culex quinquefasciatus that achieves extended population suppression but is designed to fade out over time rather than persist permanently in wild populations, a feature intended to address ecological and regulatory concerns.²⁷

None of these genetic tools have been released into wild mosquito populations yet. The gap between cage experiments and open-field deployment is large, involving regulatory approvals, public acceptance, ecological risk assessments, and the practical challenge of sustaining releases across the enormous geographic areas where these mosquitoes live. But the pace of development has been faster than most researchers expected a decade ago.

Vaccines on the Horizon

Vaccine development for mosquito-borne diseases has historically lagged behind, in part because the viruses involved mutate quickly and because, as the dengue case illustrates, partial immunity can sometimes make things worse rather than better. Yellow fever is the long-standing success story: its live-attenuated vaccine has been available since the 1930s and remains highly effective. Japanese encephalitis also has effective vaccines in use across Asia.

The newer frontier is mRNA technology, adapted from the COVID-19 vaccine platform. mRNA vaccine candidates against dengue, Zika, and chikungunya are in various stages of development and clinical trials, with improvements in mRNA stability and lipid nanoparticle delivery systems helping to boost immune responses.²⁸ For malaria, the RTS,S vaccine (marketed as Mosquirix) became the first malaria vaccine recommended by the World Health Organization in 2021, and a second-generation vaccine, R21/Matrix-M, followed with higher efficacy in clinical trials. Neither eliminates malaria on its own, but combined with bed nets and treatment, they represent a genuine shift in what is achievable against a parasite that has co-evolved with humans for millennia.

The broader challenge is distribution. Many of the populations most affected by mosquito-borne diseases live in regions with limited cold-chain infrastructure, weak health systems, and competing public health priorities. A vaccine that works brilliantly in a clinical trial but cannot reach the children who need it most has limited real-world impact, and closing that gap remains one of the defining problems in global health.